Simon A. Menaker

Simon A. Menaker

Auto-generated profile, based on publicly available information

Simon A. Menaker

Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2019 in Operative Neurosurgery
Verified
Journal Article
Closed access
PDF file
DEDaniel G. Eichberg
Daniel G. Eichberg
SMSimon A Menaker
Simon A Menaker
WJWalter J Jermakowicz
Walter J Jermakowicz
ASAshish H Shah
Ashish H Shah
ELEvan M Luther
Evan M Luther
Michael E. IvanMichael E. Ivan
Michael E. Ivan
BACKGROUND: Prior treatment with magnetic resonance-guided, laser-induced thermal therapy (LITT) is widely assumed not to be a contraindication for further treatment of brain lesions, including further iterations of LITT. However, the safety and efficacy of repeat LITT treatments have never been formally investigated. OBJECTIVE: To evaluate treatment with multiple iterations of LITT. METHODS: All patients treated with LITT at least twice at our institution were included in the study. Outcomes and neurological examinations from before and after surgery were retrospectively examined from clinic notes. Perilesonal edema was determined at various timepoints using volumetric data derived from manual tracings of fluid-attenuated inversion recovery (FLAIR) enhancement on magnetic resonance imaging (MRI). Finally, a literature review of prior cases of repeat LITT was performed. RESULTS: A total of 9 patients underwent 18 treatments with LITT; all but 1 of whom were treated for metastatic brain lesions. One patient had a transient cerebrospinal fluid leak, whereas a second patient had a superficial wound infection, both of which resolved with standard medical care. The remaining 7 patients tolerated all LITT procedures without complication. Analysis of perilesional edema volume demonstrated a correlation with the amount of energy delivered during LITT. Literature review found 5 published papers describing 9 patients who underwent LITT more than once, the majority of whom tolerated repeat LITT well. CONCLUSION: LITT is a safe and promising treatment modality and may be used multiple times without issue. There appears to be an association between the amount of energy delivered during a LITT session and the degree of postoperative perilesional edema.

22 August 2018 in Cureus
Verified
Journal Article
Open access
PDF file
DEDaniel G. Eichberg
Daniel G. Eichberg
SMSimon A Menaker
Simon A Menaker
SBSimon S. Buttrick
Simon S. Buttrick
SGSakir H. Gultekin
Sakir H. Gultekin
Ricardo J. KomotarRicardo J. Komotar
Ricardo J. Komotar
We describe all cases of nasoethmoid schwannomas with intracranial extension reported in the literature, including an original case report describing the successful gross total resection of a nasoethmoid schwannoma with intracranial extension. Ten cases of nasoethmoid schwannoma with intracranial extension have previously been reported. These lesions most often appear in the second through fourth decades of life and commonly present with anosmia, headache, and visual deficits. Bifrontal craniotomy was the predominantly implemented surgical approach and gross total resection was achieved in all cases, except for one. In conclusion, nasoethmoid schwannoma with intracranial extension is a rare disease entity that is most often benign and is most commonly treated by gross total resection using a bifrontal craniotomy approach.

3 August 2026 in Journal of Neurosurgery: Case Lessons
Verified
Journal Article
Open access
SMSimon A. Menaker
Simon A. Menaker
MMMichelot Michel
Michelot Michel
CGCatherine M. Garcia
Catherine M. Garcia
EREdward Robinson
Edward Robinson
XFXuemo Fan
Xuemo Fan
JYJohn S. Yu
John S. Yu
BACKGROUND: Vestibular schwannomas (VSs) are common benign tumors of the cerebellopontine angle, often treated with surgery or stereotactic radiosurgery to preserve nerve function. Malignant transformation of VS (MTVS) is exceedingly rare and has been primarily associated with neurofibromatosis type 1 (NF1), neurofibromatosis type 2–related schwannomatosis (NF2-SWN), or prior radiation exposure. However, cases of MTVS occurring without these risk factors are rare and remain poorly understood. OBSERVATIONS: A 58-year-old woman without neurofibromatosis underwent subtotal VS resection in 2019, with stable residual tumor and no adjuvant treatment. In 2023, she developed acute neurological decline, and imaging suggested malignant transformation or a new tumor. Surgery confirmed a high-grade neoplasm, likely leiomyosarcoma or malignant peripheral nerve sheath tumor, with genetic analysis revealing no NF1 or NF2-SWN mutations. She received adjuvant stereotactic radiation therapy, and at the 3-month follow-up, imaging showed stable residual disease. However, she continued to experience persistent neurological deficits, including facial weakness, ataxia, and intention tremor, with a Karnofsky Performance Scale score of 60%. LESSONS: MTVS is extremely rare without neurofibromatosis or prior radiation therapy, potentially driven by surgical inflammation or unidentified genetic alterations. While increased surveillance after subtotal resection may be considered, more research is needed to identify predictive markers and guide clinical management. https://thejns.org/doi/10.3171/CASE251003

12 May 2025 in Journal of Neurosurgery: Case Lessons
Verified
Journal Article
Open access
PDF file
SMSimon A. Menaker
Simon A. Menaker
ABAndre Everett Boyke
Andre Everett Boyke
SBSerguei I. Bannykh
Serguei I. Bannykh
ZAZiedulla Abdullaev
Ziedulla Abdullaev
LRLindsey B. Ross
Lindsey B. Ross
PEPaula Eboli
Paula Eboli
BACKGROUND: Anaplastic pleomorphic xanthoastrocytomas (APXAs) are rare, grade 3 malignant glial neoplasms first described as a distinct entity in the 2016 WHO classification of tumors of the CNS. They are generally seen in pediatric and young adult patients as supratentorial lesions with both solid and cystic components and have a high propensity for recurrence. APXAs occasionally demonstrate leptomeningeal dissemination (LMD) but very rarely at diagnosis. OBSERVATIONS: The authors describe the case of a 36-year-old male with a history of seizures and a known left temporal lesion since childhood, serially imaged and never biopsied, who presented with headache, increasingly frequent seizures, and right third nerve palsy. Imaging demonstrated significant interval enlargement of the lesion with intralesional hemorrhage and predominantly locoregional leptomeningeal enhancement. He underwent resection with gross-total resection achieved, and pathology revealed WHO grade 3 pleomorphic xanthoastrocytoma with ATG7::RAF1 fusion, 9p21 deletion, and telomerase reverse transcriptase promoter mutation, as identified by next-generation sequencing. This was followed by adjuvant whole-brain radiation therapy with boost and treatment with the MEK inhibitor cobimetinib. LESSONS: APXA, an already exceedingly rare primary CNS tumor, can present unusually in older adult patients with concomitant LMD and cranial neuropathy. Advanced genomic profiling can tailor adjuvant therapy. https://thejns.org/doi/10.3171/CASE24768

26 October 2025 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Open access
MMMichelot Michel
Michelot Michel
ANAlan Nguyen
Alan Nguyen
SSShane Shahrestani
Shane Shahrestani
EREdward Robinson
Edward Robinson
ABAndre Everett Boyke
Andre Everett Boyke
RCRay M. Chu
Ray M. Chu
Navigated suction devices may enhance intraoperative efficiency and maximize safe resection of infiltrative gliomas by providing real-time anatomical guidance. However, their use and safety in high-grade glioma (HGG) surgery is unreported. We evaluated the safety and feasibility of a neuronavigation-integrated suction (NIS) device compared to conventional neuronavigation in patients undergoing resection for HGGs. We utilized an NIS device in 33 HGG (WHO grade III/IV) resections. We retrospectively collected data on 174 HGG resections using standard neuronavigation during the same period, then performed propensity score matching (age, sex, prior treatment, tumor grade, tumor location, IDH status) to create 33 matched pairs (NIS vs. control, n = 66). Outcomes included extent of resection, operative time, estimated blood loss (EBL), complications, and length of stay (LOS). Baseline characteristics, including age (P = 0.299), sex (P = 0.319), tumor laterality (P = 0.196), anatomic location (P = 0.861), eloquent area (P = 0.769), tumor grade (P = 1.000), IDH mutation status (P = 0.415), prior resection (P = 0.602), and prior radiation therapy (P = 0.071), were comparable between groups. The NIS group had shorter operative times (193.7 ± 52.0 vs. 230.5 ± 69.2 min, P = 0.009). Intended GTR was more common with NIS (95 % vs. 65.2 %, P = 0.017). LOS was shorter in the NIS group (median 2.0 [1.75, 2.25] vs. 2.0 [1.5, 13.0] days, P = 0.030) with fewer postoperative complications (6.1 % vs. 30.3 %, P = 0.011). EBL (P = 0.418) and intraoperative complications (P = 0.314) were similar. Recurrence (57.6 %) and six-month mortality (21.2 %) were similar; there was no significant difference in median overall survival (control: 362 [110.5, 498.8] vs. NIS: 428 [177.5, 536] days, P = 0.237). The NIS device was feasible to use in high-grade glioma surgery, and its use did not appear to compromise resection quality, complication rates, or oncologic outcomes. As neuronavigation and real-time intraoperative technologies advance, integrating such tools may further enhance surgical precision and patient outcomes for infiltrative gliomas. Future prospective, randomized studies should refine this technology and explore its broader impact on neurosurgical practice.